## In the claims:

## 1. (Original) A compound represented by formula I

or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, wherein

R<sub>a</sub> and R<sub>b</sub> are independently selected from the group consisting of hydrogen, halogen, hydroxy, nitro, amino, substituted amino, mercapto, polyfluoroalkyl, C<sub>1-6</sub> alkyl, substituted C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylthio, formyl, carboxyl, aryl or heteroaryl;

Linker is selected from the group consisting of C2 alkyl, C2 alkenyl, C2 alkynyl,

X is O, S,  $-C(R_1)_2$ , C=O,  $-C(R_1)_2$ Y-- or  $--YC(R_1)_2$ --, wherein Y is selected from the group consisting of O, S and  $C(R_2)_2$ , wherein  $R_1$  and  $R_2$  are, independently, hydrogen or methyl; and Z is hydrogen or C1-6 alkyl.

## 2. (Original) A compound represented by formula I

$$R_a$$
 Linker  $R_b$ 

or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, wherein

R<sub>a</sub> and R<sub>b</sub> are independently selected from the group consisting of hydrogen, halogen, hydroxy, nitro, amino, mercapto, CF<sub>3</sub>, C<sub>1-6</sub> alkyl, halosubstituted C<sub>1-6</sub> alkyl, hydroxy-substituted C<sub>1-6</sub> alkyl, aminosubstituted C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, formyl, carboxyl, mono- or di-C<sub>1-6</sub> alkyl-substituted amino, aryl or heteroaryl;

Linker is selected from the group consisting of --CH=CH--, --C≅C--, --C(=O)-NH--, --NH-C(=O)--, --CH<sub>2</sub>O--, --O-C(=O)--, --C(=S)-NH--, --C(=O)-O--, --C(=O)-S--, --S-C(=O)--, --S-CH<sub>2</sub>--, --CH<sub>2</sub>-CH<sub>2</sub>--, --CH<sub>2</sub>-NH--, --C(=O)-CH<sub>2</sub>--, --NH-C(=S)--, --CH<sub>2</sub>S--, --OCH<sub>2</sub> --, --NHCH<sub>2</sub> or --CRc=CRd--, wherein Rc and Rd are independently hydrogen or C1-6 alkyl;

X is O, S,  $-C(R_1)_2$ , C=O,  $-C(R_1)_2$ Y-- or  $--YC(R_1)_2$ --, wherein Y is selected from the group consisting of O, S and  $C(R_2)_2$ , and  $R_1$  and  $R_2$  are, independently, hydrogen or methyl; and Z is hydrogen or C1-6 alkyl.

- 3. (Original) The compound of claim 2 wherein X is  $-C(R_1)_2Y$  or  $-YC(R_1)_2$ —, wherein Y is selected from the group consisting of O, S and  $C(R_2)_2$  and  $R_1$  and  $R_2$  are, independently, hydrogen or methyl.
  - 4. Cancelled
  - 5. (Original) The compound of claim 3 wherein Linker is --CH=CH- or --C≡C--.
  - 6. Cancelled
  - 7. Cancelled
  - 8. Cancelled
  - 9. Cancelled
- 10. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier therefor.
- 11. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 2 and a pharmaceutically acceptable carrier therefor.

12. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 3 and a pharmaceutically acceptable carrier therefor.
 13. Cancelled

13. Cancelled
14. Cancelled
15. Cancelled
16. Cancelled
17. Cancelled
18. Cancelled
19. Cancelled

20.

Cancelled